Benitec Biopharma to Participate in Upcoming Conferences in March
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced its participation in three major healthcare conferences in March 2025.
The company will present at:
- TD Cowen 45th Annual Health Care Conference on March 5, 2025 (9:50-10:20 AM EST)
- Leerink Partners Global Healthcare Conference on March 12, 2025 (9:20-9:50 AM EST)
- 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, TX, featuring two sessions on March 18-19, 2025, focusing on Oculopharyngeal Muscular Dystrophy and Clinical Trial Updates
All presentations will be available via live webcast, and one-on-one meetings can be scheduled with management.
Benitec Biopharma (NASDAQ: BNTC), un'azienda biotecnologica in fase clinica specializzata nella terapia genica e nella piattaforma di interferenza RNA diretta da DNA 'Silence and Replace' (ddRNAi), ha annunciato la sua partecipazione a tre importanti conferenze sanitarie a marzo 2025.
L'azienda presenterà a:
- TD Cowen 45ª Conferenza Annuale sulla Salute il 5 marzo 2025 (9:50-10:20 AM EST)
- Conferenza Globale sulla Salute di Leerink Partners il 12 marzo 2025 (9:20-9:50 AM EST)
- Conferenza Clinica e Scientifica 2025 dell'Associazione Distrofia Muscolare a Dallas, TX, con due sessioni il 18-19 marzo 2025, incentrate sulla Distrofia Muscolare Oculofaringea e sugli Aggiornamenti delle Sperimentazioni Cliniche
Tutte le presentazioni saranno disponibili tramite webcast in diretta e sarà possibile programmare incontri individuali con il management.
Benitec Biopharma (NASDAQ: BNTC), una empresa biotecnológica en etapa clínica especializada en terapia génica y la plataforma de interferencia de ARN dirigida por ADN 'Silence and Replace' (ddRNAi), ha anunciado su participación en tres importantes conferencias de salud en marzo de 2025.
La empresa presentará en:
- 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo de 2025 (9:50-10:20 AM EST)
- Conferencia Global de Salud de Leerink Partners el 12 de marzo de 2025 (9:20-9:50 AM EST)
- Conferencia Clínica y Científica 2025 de la Asociación de Distrofia Muscular en Dallas, TX, con dos sesiones el 18-19 de marzo de 2025, centrándose en la Distrofia Muscular Oculofaringea y Actualizaciones de Ensayos Clínicos
Todas las presentaciones estarán disponibles a través de una transmisión en vivo, y se pueden programar reuniones uno a uno con la dirección.
Benitec Biopharma (NASDAQ: BNTC)는 유전자 치료와 'Silence and Replace' DNA 지향 RNA 간섭(ddRNAi) 플랫폼을 전문으로 하는 임상 단계의 생명공학 회사로, 2025년 3월에 열리는 세 가지 주요 의료 회의에 참여한다고 발표했습니다.
회사는 다음과 같은 회의에서 발표할 예정입니다:
- TD Cowen 제45회 연례 의료 회의 2025년 3월 5일 (오전 9:50-10:20 EST)
- Leerink Partners 글로벌 의료 회의 2025년 3월 12일 (오전 9:20-9:50 EST)
- 2025 근육 위축 협회 임상 및 과학 회의 텍사스주 댈러스에서 2025년 3월 18-19일에 두 세션이 열리며, 안구인두 근육 위축 및 임상 시험 업데이트에 중점을 둡니다.
모든 발표는 라이브 웹캐스트를 통해 제공되며, 경영진과의 일대일 회의를 예약할 수 있습니다.
Benitec Biopharma (NASDAQ: BNTC), une entreprise de biotechnologie en phase clinique spécialisée dans la thérapie génique et la plateforme d'interférence ARN dirigée par ADN 'Silence and Replace' (ddRNAi), a annoncé sa participation à trois grandes conférences sur la santé en mars 2025.
L'entreprise présentera lors des événements suivants :
- 45ème Conférence Annuelle sur la Santé de TD Cowen le 5 mars 2025 (9h50-10h20 EST)
- Conférence Mondiale sur la Santé de Leerink Partners le 12 mars 2025 (9h20-9h50 EST)
- Conférence Clinique et Scientifique 2025 de l'Association de Dystrophie Musculaire à Dallas, TX, avec deux sessions les 18 et 19 mars 2025, axées sur la Dystrophie Musculaire Oculopharyngée et les Mises à Jour des Essais Cliniques
Toutes les présentations seront disponibles via un webinaire en direct, et des réunions individuelles peuvent être planifiées avec la direction.
Benitec Biopharma (NASDAQ: BNTC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapie und die 'Silence and Replace' DNA-gesteuerte RNA-Interferenz (ddRNAi) Plattform spezialisiert hat, hat seine Teilnahme an drei wichtigen Gesundheitskonferenzen im März 2025 angekündigt.
Das Unternehmen wird auf folgenden Veranstaltungen präsentieren:
- 45. TD Cowen Jahreskonferenz für Gesundheitswesen am 5. März 2025 (9:50-10:20 Uhr EST)
- Leerink Partners Globale Gesundheitskonferenz am 12. März 2025 (9:20-9:50 Uhr EST)
- 2025 Konferenz für klinische und wissenschaftliche Forschung der Muskulären Dystrophie Vereinigung in Dallas, TX, mit zwei Sitzungen am 18.-19. März 2025, die sich auf oculopharyngeale Muskeldystrophie und Aktualisierungen klinischer Studien konzentrieren
Alle Präsentationen werden über einen Live-Webcast verfügbar sein, und es können Einzelgespräche mit der Geschäftsleitung vereinbart werden.
- None.
- None.
HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences.
TD Cowen 45th Annual Health Care Conference
Date: March 5, 2025
Time of Presentation: 9:50 AM to 10:20 AM EST
Format: Presentation & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Leerink Partners Global Healthcare Conference 2025
Date: March 12, 2025
Time of Presentation: 9:20 AM to 9:50 AM EST
Format: Fireside Chat & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
2025 Muscular Dystrophy Association Clinical & Scientific Conference
Session: Pre-clinical and Clinical Efforts in Oculopharyngeal Muscular Dystrophy
Date & Time of Panel Discussion: March 18th, 2025 from 11:00 AM to 12:00 PM CST
Location: Dallas, TX
Session: Clinical Trial Updates, Late-Breaking Oral Abstracts
Date & Time of Presentation: March 19th, 2025 from 1:15 PM to 1:30 PM CST
Location: Dallas, TX
Please contact your conference representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
